Intestinal microbiome Gut flora
Conditions
Interventions
A 6-week intervention period during which study participants take one of nine fiber supplements or a control supplement twice daily.
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age 18 years and older;Body mass index (BMI) =18 and =30 kg/m2Willing to keep a stable lifestyle, both diet and exercise, during the study period
Exclusion criteria
Exclusion criteria: Any known/diagnosed metabolic, gastrointestinal, inflammatory or chronic disease (such as anemia, diabetes, hepatitis, cardiovascular disease) that may significantly affect the study outcome or increase participant risk (judged by medical doctor);Having a history of medical or surgical events that may significantly affect the study outcome (judged by medical doctor), including: Inflammatory bowel disease, hepatitis, pancreatitis, ulcers, gastrointestinal or rectal bleeding; major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; known or suspected gastrointestinal disorders, colon or GI tract cancer;Use of medication that may impact gastric emptying (e.g. gastric acid inhibitors or laxatives);Having a habitual dietary fiber intake of >25 grams (females) or >30 grams (males) a day, as calculated from the FiberScreen questionnaire during screening;Having less than 3 bowel movements per week, or more than 3 per day;Being gluten intolerant or having a corn allergy (self-reported);Use of antibiotic treatment less than 3 month before start of the study and during the study;Use of prebiotic, probiotic or postbiotic supplements (must be stopped at least 4 weeks before the first test day);Following a diet avoiding FODMAPSReporting to follow or having planned a slimming or medically prescribed diet.Average alcohol intake >14 (women) or >21 (men) of alcoholic units per week;Abuse of illicit drugs;Insufficient proficiency in Dutch to understand information brochure and questionnaires;Participation in any clinical trial including blood sampling and/or administration of substances up to 4 weeks before test day 1 of this study and during the study period;Being an employee of the department Food, Health & Consumer Research of Wageningen Food & Biobased Research (WFBR).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in relative abundance of CAZyme-encoding genes (GH [sub-]families) in fecal metagenomes. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in microbiome composition based on fecal metagenomes. | — |
Countries
Netherlands
Contacts
Public ContactLM Janssen Duijghuijsen
Wageningen Universiteit
Outcome results
None listed